BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31778662)

  • 1. Globotriaosylceramide-induced reduction of K
    Rickert V; Kramer D; Schubert AL; Sommer C; Wischmeyer E; Üçeyler N
    Exp Neurol; 2020 Feb; 324():113134. PubMed ID: 31778662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated interleukin-8 expression by skin fibroblasts as a potential contributor to pain in women with Fabry disease.
    Hofmann L; Grüner J; Klug K; Breyer M; Klein T; Hochheimer V; Wagenhäuser L; Wischmeyer E; Üçeyler N
    PLoS One; 2024; 19(4):e0300687. PubMed ID: 38593151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-α links heat and inflammation with Fabry pain.
    Üçeyler N; Urlaub D; Mayer C; Uehlein S; Held M; Sommer C
    Mol Genet Metab; 2019 Jul; 127(3):200-206. PubMed ID: 31221509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.
    Üçeyler N; Schröter N; Kafke W; Kramer D; Wanner C; Weidemann F; Sommer C
    PLoS One; 2016; 11(11):e0166484. PubMed ID: 27851774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
    Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
    Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
    Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy.
    Liguori R; Incensi A; de Pasqua S; Mignani R; Fileccia E; Santostefano M; Biagini E; Rapezzi C; Palmieri S; Romani I; Borsini W; Burlina A; Bombardi R; Caprini M; Avoni P; Donadio V
    PLoS One; 2017; 12(7):e0180581. PubMed ID: 28672034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different expression of β subunits of the KCa1.1 channel by invasive and non-invasive human fibroblast-like synoviocytes.
    Pethő Z; Tanner MR; Tajhya RB; Huq R; Laragione T; Panyi G; Gulko PS; Beeton C
    Arthritis Res Ther; 2016 May; 18(1):103. PubMed ID: 27165430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
    Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
    Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of small fiber pathology in a mouse model of Fabry disease.
    Hofmann L; Hose D; Grießhammer A; Blum R; Döring F; Dib-Hajj S; Waxman S; Sommer C; Wischmeyer E; Üçeyler N
    Elife; 2018 Oct; 7():. PubMed ID: 30328411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients.
    Hsu MJ; Chang FP; Lu YH; Hung SC; Wang YC; Yang AH; Lee HJ; Sung SH; Wang YF; Yu WC; Hsu TR; Huang PH; Chang SK; Dzhagalov I; Hsu CL; Niu DM
    Genet Med; 2019 Jan; 21(1):224-232. PubMed ID: 29875425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal globotriaosylceramide deposits for Fabry disease linked to uncertain pathogenicity gene variant c.352C>T/p.Arg118Cys: A family study.
    Cerón-Rodríguez M; Ramón-García G; Barajas-Colón E; Franco-Álvarez I; Salgado-Loza JL
    Mol Genet Genomic Med; 2019 Nov; 7(11):e981. PubMed ID: 31566927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy.
    Lee MH; Choi EN; Jeon YJ; Jung SC
    Int J Mol Med; 2012 Dec; 30(6):1275-80. PubMed ID: 23007467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered globotriaosylceramide accumulation and mucosal neuronal fiber density in the colon of the Fabry disease mouse model.
    Masotti M; Delprete C; Dothel G; Donadio V; Rimondini R; Politei JM; Liguori R; Caprini M
    Neurogastroenterol Motil; 2019 Mar; 31(3):e13529. PubMed ID: 30609268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lyso-Gb3 activates Notch1 in human podocytes.
    Sanchez-Niño MD; Carpio D; Sanz AB; Ruiz-Ortega M; Mezzano S; Ortiz A
    Hum Mol Genet; 2015 Oct; 24(20):5720-32. PubMed ID: 26206887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.
    Biancini GB; Vanzin CS; Rodrigues DB; Deon M; Ribas GS; Barschak AG; Manfredini V; Netto CB; Jardim LB; Giugliani R; Vargas CR
    Biochim Biophys Acta; 2012 Feb; 1822(2):226-32. PubMed ID: 22085605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease.
    Morimoto H; Ito Y; Yoden E; Horie M; Tanaka N; Komurasaki Y; Yamamoto R; Mihara K; Minami K; Hirato T
    Mol Genet Metab; 2018 Sep; 125(1-2):153-160. PubMed ID: 30054149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KCa1.1 inhibition attenuates fibroblast-like synoviocyte invasiveness and ameliorates disease in rat models of rheumatoid arthritis.
    Tanner MR; Hu X; Huq R; Tajhya RB; Sun L; Khan FS; Laragione T; Horrigan FT; Gulko PS; Beeton C
    Arthritis Rheumatol; 2015 Jan; 67(1):96-106. PubMed ID: 25252152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.
    Valbuena C; Leitão D; Carneiro F; Oliveira JP
    Virchows Arch; 2012 Feb; 460(2):211-21. PubMed ID: 22205110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.